{"id":1306,"date":"2023-11-12T23:51:18","date_gmt":"2023-11-12T23:51:18","guid":{"rendered":"https:\/\/economicherald.net\/?p=1306"},"modified":"2023-11-12T23:51:18","modified_gmt":"2023-11-12T23:51:18","slug":"argenica-gets-cash-boost-ahead-of-critical-phase-2-clinical-trial","status":"publish","type":"post","link":"https:\/\/economicherald.net\/?p=1306","title":{"rendered":"Argenica gets cash boost ahead of critical Phase 2 clinical trial"},"content":{"rendered":"

Argenica receives $2.089 million via R&D Tax Incentive Program to continue developing its ARG-007 lead drug
\nFunds will be invested in upcoming Phase 2 clinical trial on ischaemic stroke patients
\nHospitals across all major Australian cities confirmed to be participating in the double-blind study<\/p>\n

\u00a0<\/p>\n

Special Report<\/em>: Argenica Therapeutics has received a R&D cash rebate of almost $2.1 million, which can be applied to further developing ARG-007, including investing back into the upcoming Phase 2 clinical trial on ischaemic stroke patients.<\/strong><\/p>\n

Perth-based Argenica Therapeutics (ASX: AGN)<\/a> is developing novel therapeutics to reduce brain tissue death after stroke, other types of brain injury, and neurodegenerative diseases.<\/p>\n

Argenica\u2019s lead neuroprotective peptide candidate ARG-007 has already successfully demonstrated improved outcomes in pre-clinical stroke models, traumatic brain injury (TBI) and hypoxic ischaemic encephalopathy (HIE).<\/p>\n

The ~$2.1m received from the Australian Government\u2019s R&D Tax Incentive Program will be used to continue development of ARG-007. The company was recently given the green light to undertake the Phase 2 \u201cproof of concept\u201d clinical trial of its lead drug for acute ischaemic stroke patients.<\/p>\n

Major hospitals in WA, South Australia, VIC, NSW and QLD have all confirmed their participation in the upcoming trial with site governance due to be completed later this quarter.<\/p>\n

Eligible patients will receive either a single intravenous dose of ARG-007 or saline placebo prior to undergoing a thrombectomy procedure. The trial will be completed as a double-blind study.<\/p>\n

\u00a0<\/p>\n

\u2018<\/strong>Vital for supporting Australian innovation\u2019<\/strong>\u00a0<\/strong><\/h2>\n

An \u201cadvance and overseas\u201d finding has also been approved by AusIndustry, enabling both domestic and overseas expenditure on Argenica\u2019s planned pre-clinical efficacy, non-clinical studies, manufacturing, regulatory activities and Phase 2 clinical trial requirements to be included as eligible R&D expenditure for the next three financial years.<\/p>\n

Argenica managing director Dr Liz Dallimore said the R&D Tax Incentive Program was vital for supporting Australian innovation.<\/p>\n

\u201cThese funds will be applied to further developing the company\u2019s lead neuroprotective peptide candidate, ARG-007, including an upcoming Phase 2 clinical trial in ischaemic stroke patients, as well as continuing to generate pre-clinical data in other neurological conditions, including in TBI, HIE and Alzheimer\u2019s Disease,\u201d she said.<\/p>\n

The recently completed Phase 1 clinical trial in healthy human volunteers assessed the safety and tolerability of a single dose of ARG-007<\/p>\n

Pre-clinical data has also shown ARG-007 inhibits another of the main abnormal proteins which causes Alzheimer\u2019s Disease.<\/p>\n

\u00a0<\/p>\n\n

\u00a0<\/p>\n

This article was developed in collaboration with Argenica Therapeutics, a Stockhead advertiser at the time of publishing.<\/em><\/p>\n

\u00a0<\/p>\n

This article does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.<\/em><\/p>\n

<\/span><\/p>\n

The post Argenica gets cash boost ahead of critical Phase 2 clinical trial<\/a> appeared first on Stockhead<\/a>.<\/p>","protected":false},"excerpt":{"rendered":"

Argenica receives $2.089 million via R&D Tax Incentive Program to continue developing its ARG-007 lead drug Funds will be invested in upcoming Phase 2 clinical [more…]<\/a><\/p>\n","protected":false},"author":0,"featured_media":1307,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[],"class_list":["post-1306","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-finance"],"yoast_head":"\nArgenica gets cash boost ahead of critical Phase 2 clinical trial - Economic Herald<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/economicherald.net\/?p=1306\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Argenica gets cash boost ahead of critical Phase 2 clinical trial - Economic Herald\" \/>\n<meta property=\"og:description\" content=\"Argenica receives $2.089 million via R&D Tax Incentive Program to continue developing its ARG-007 lead drug Funds will be invested in upcoming Phase 2 clinical [more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/economicherald.net\/?p=1306\" \/>\n<meta property=\"og:site_name\" content=\"Economic Herald\" \/>\n<meta property=\"article:published_time\" content=\"2023-11-12T23:51:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/economicherald.net\/wp-content\/uploads\/2023\/11\/GettyImages-1352251601-injection-1-LVqu1R.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"675\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=1306#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=1306\"},\"author\":{\"name\":\"\",\"@id\":\"\"},\"headline\":\"Argenica gets cash boost ahead of critical Phase 2 clinical trial\",\"datePublished\":\"2023-11-12T23:51:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=1306\"},\"wordCount\":458,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=1306#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/economicherald.net\\\/wp-content\\\/uploads\\\/2023\\\/11\\\/GettyImages-1352251601-injection-1-LVqu1R.jpeg\",\"articleSection\":[\"Finance\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/economicherald.net\\\/?p=1306#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=1306\",\"url\":\"https:\\\/\\\/economicherald.net\\\/?p=1306\",\"name\":\"Argenica gets cash boost ahead of critical Phase 2 clinical trial - Economic Herald\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=1306#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=1306#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/economicherald.net\\\/wp-content\\\/uploads\\\/2023\\\/11\\\/GettyImages-1352251601-injection-1-LVqu1R.jpeg\",\"datePublished\":\"2023-11-12T23:51:18+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=1306#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/economicherald.net\\\/?p=1306\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=1306#primaryimage\",\"url\":\"https:\\\/\\\/economicherald.net\\\/wp-content\\\/uploads\\\/2023\\\/11\\\/GettyImages-1352251601-injection-1-LVqu1R.jpeg\",\"contentUrl\":\"https:\\\/\\\/economicherald.net\\\/wp-content\\\/uploads\\\/2023\\\/11\\\/GettyImages-1352251601-injection-1-LVqu1R.jpeg\",\"width\":1200,\"height\":675},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=1306#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/economicherald.net\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Argenica gets cash boost ahead of critical Phase 2 clinical trial\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/economicherald.net\\\/#website\",\"url\":\"https:\\\/\\\/economicherald.net\\\/\",\"name\":\"Economic Herald\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/economicherald.net\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/economicherald.net\\\/#organization\",\"name\":\"Economic Herald\",\"url\":\"https:\\\/\\\/economicherald.net\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/economicherald.net\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/economicherald.net\\\/wp-content\\\/uploads\\\/2023\\\/10\\\/cropped-cropped-economicheraldlogo-1.png\",\"contentUrl\":\"https:\\\/\\\/economicherald.net\\\/wp-content\\\/uploads\\\/2023\\\/10\\\/cropped-cropped-economicheraldlogo-1.png\",\"width\":850,\"height\":760,\"caption\":\"Economic Herald\"},\"image\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Argenica gets cash boost ahead of critical Phase 2 clinical trial - Economic Herald","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/economicherald.net\/?p=1306","og_locale":"en_US","og_type":"article","og_title":"Argenica gets cash boost ahead of critical Phase 2 clinical trial - Economic Herald","og_description":"Argenica receives $2.089 million via R&D Tax Incentive Program to continue developing its ARG-007 lead drug Funds will be invested in upcoming Phase 2 clinical [more...]","og_url":"https:\/\/economicherald.net\/?p=1306","og_site_name":"Economic Herald","article_published_time":"2023-11-12T23:51:18+00:00","og_image":[{"width":1200,"height":675,"url":"https:\/\/economicherald.net\/wp-content\/uploads\/2023\/11\/GettyImages-1352251601-injection-1-LVqu1R.jpeg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/economicherald.net\/?p=1306#article","isPartOf":{"@id":"https:\/\/economicherald.net\/?p=1306"},"author":{"name":"","@id":""},"headline":"Argenica gets cash boost ahead of critical Phase 2 clinical trial","datePublished":"2023-11-12T23:51:18+00:00","mainEntityOfPage":{"@id":"https:\/\/economicherald.net\/?p=1306"},"wordCount":458,"commentCount":0,"publisher":{"@id":"https:\/\/economicherald.net\/#organization"},"image":{"@id":"https:\/\/economicherald.net\/?p=1306#primaryimage"},"thumbnailUrl":"https:\/\/economicherald.net\/wp-content\/uploads\/2023\/11\/GettyImages-1352251601-injection-1-LVqu1R.jpeg","articleSection":["Finance"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/economicherald.net\/?p=1306#respond"]}]},{"@type":"WebPage","@id":"https:\/\/economicherald.net\/?p=1306","url":"https:\/\/economicherald.net\/?p=1306","name":"Argenica gets cash boost ahead of critical Phase 2 clinical trial - Economic Herald","isPartOf":{"@id":"https:\/\/economicherald.net\/#website"},"primaryImageOfPage":{"@id":"https:\/\/economicherald.net\/?p=1306#primaryimage"},"image":{"@id":"https:\/\/economicherald.net\/?p=1306#primaryimage"},"thumbnailUrl":"https:\/\/economicherald.net\/wp-content\/uploads\/2023\/11\/GettyImages-1352251601-injection-1-LVqu1R.jpeg","datePublished":"2023-11-12T23:51:18+00:00","breadcrumb":{"@id":"https:\/\/economicherald.net\/?p=1306#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/economicherald.net\/?p=1306"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/economicherald.net\/?p=1306#primaryimage","url":"https:\/\/economicherald.net\/wp-content\/uploads\/2023\/11\/GettyImages-1352251601-injection-1-LVqu1R.jpeg","contentUrl":"https:\/\/economicherald.net\/wp-content\/uploads\/2023\/11\/GettyImages-1352251601-injection-1-LVqu1R.jpeg","width":1200,"height":675},{"@type":"BreadcrumbList","@id":"https:\/\/economicherald.net\/?p=1306#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/economicherald.net\/"},{"@type":"ListItem","position":2,"name":"Argenica gets cash boost ahead of critical Phase 2 clinical trial"}]},{"@type":"WebSite","@id":"https:\/\/economicherald.net\/#website","url":"https:\/\/economicherald.net\/","name":"Economic Herald","description":"","publisher":{"@id":"https:\/\/economicherald.net\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/economicherald.net\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/economicherald.net\/#organization","name":"Economic Herald","url":"https:\/\/economicherald.net\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/economicherald.net\/#\/schema\/logo\/image\/","url":"https:\/\/economicherald.net\/wp-content\/uploads\/2023\/10\/cropped-cropped-economicheraldlogo-1.png","contentUrl":"https:\/\/economicherald.net\/wp-content\/uploads\/2023\/10\/cropped-cropped-economicheraldlogo-1.png","width":850,"height":760,"caption":"Economic Herald"},"image":{"@id":"https:\/\/economicherald.net\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/economicherald.net\/index.php?rest_route=\/wp\/v2\/posts\/1306","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/economicherald.net\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/economicherald.net\/index.php?rest_route=\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/economicherald.net\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=1306"}],"version-history":[{"count":0,"href":"https:\/\/economicherald.net\/index.php?rest_route=\/wp\/v2\/posts\/1306\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/economicherald.net\/index.php?rest_route=\/wp\/v2\/media\/1307"}],"wp:attachment":[{"href":"https:\/\/economicherald.net\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=1306"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/economicherald.net\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=1306"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/economicherald.net\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=1306"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}